BPC-157 FDA Status After the 2026 Advisory Vote

Current status: BPC-157 is not FDA-approved, is not on the 503A bulk drug substances list, and cannot legally be compounded by a US pharmacy today. On July 23, 2026 an FDA advisory committee recommended that it be added to that list. That recommendation is non-binding, and it was made for a specific medical indication that has nothing to do with why athletes buy it.

The vote

At the July 23–24, 2026 meeting of the FDA's Pharmacy Compounding Advisory Committee (PCAC), both BPC-157 free base and BPC-157 acetate were voted on separately for inclusion on the section 503A bulks list. Each cleared by the same margin: 8–6 in favor, with one abstention¹².

Those tallies come from trade and news coverage of the meeting. The FDA has not published minutes, so we attribute them as reporting rather than as an agency record.

The indication FDA actually reviewed: ulcerative colitis

This is the part that should change how you read every headline about this vote.

The FDA published, in advance, the exact use it evaluated for each substance. For BPC-157 free base and BPC-157 acetate, the use evaluated was ulcerative colitis³.

Not tendons. Not ligaments. Not muscle tears, rotator cuffs, Achilles injuries, joint pain, or post-workout recovery. The FDA did not review BPC-157 for any athletic or musculoskeletal indication, and the committee did not vote on one. An inflammatory bowel disease is what was on the table — which makes sense given BPC-157's gastric origin, and makes no sense as a basis for the tendon-repair marketing now attaching itself to the vote.

If you are here because of the injury-recovery claims, the evidence that matters to you was not examined at this meeting and has not changed. It is still overwhelmingly rodent and cell-culture work with no robust randomized human trial behind it, which we lay out in full in BPC-157 for healing and recovery: what the evidence actually shows and, for the specific claim most people arrive with, BPC-157 for tendonitis.

What FDA's own reviewers said

The committee voted in favor over the objection of the agency's scientific staff, who recommended against adding any of the seven peptides on the agenda, citing missing human data and safety concerns⁴. Their most striking objection was more fundamental than efficacy: FDA officials told the panel they struggled to define these substances chemically at all, because material sold under the same peptide name varies considerably between sources — "we can't create quality standards until we actually know what it is"⁴.

The composition of the committee is also part of the record. Eight new members were appointed shortly before the meeting, most with ties to the peptide industry, and NBC News counted that all eight of them voted yes on BPC-157, with six members voting no and one abstaining². That is the whole favorable margin.

What still has to happen

A favorable PCAC vote does not list anything. To add BPC-157 to 21 CFR 216.23, the FDA must publish a proposed rule, take public comment, and publish a final rule⁵. Only the final rule changes the list.

For scale: the one completed 503A bulks rulemaking ran from advisory meetings in 2015–16 to a proposed rule in December 2016 to a final rule effective March 21, 2019 — roughly three years⁶. No FDA timeline has been published for this one. The "proposed rule in 9 to 18 months" figure circulating on vendor blogs has no FDA source behind it.

What you should not conclude

• •Not that BPC-157 is FDA approved. It is not, and the 503A pathway does not lead there. 21 CFR 216.23(d) states that representing a compounded drug made with a listed bulk substance as "FDA approved, or otherwise endorsed by FDA generally or for a particular indication" causes it to be misbranded under sections 502(a) and/or 502(bb) of the Act⁵. That applies after a substance wins its rulemaking, not just before it.
• •Not that the FDA endorsed BPC-157 for injuries. It reviewed ulcerative colitis. A clinician could later prescribe a listed substance outside the reviewed use at their own discretion, but that would be a prescriber's judgment, not an FDA finding about tendons.
• •Not that research-chemical vials are now legitimate. Any future listing would govern what a licensed pharmacy may compound against a prescription. It has no bearing on "research use only" material bought online, which remains an unapproved drug — see where to buy peptides and research-chemical legality.
• •Not that anything changed for tested athletes. BPC-157 remains prohibited at all times under WADA class S0, non-approved substances⁷. US compounding policy and the WADA Prohibited List are separate instruments; see the WADA 2026 prohibited list for peptides.

Where BPC-157 sits on FDA's lists today

BPC-157 is often described as "removed from Category 2," which is misleading. FDA's Category 2 page carries two tables, and BPC-157 appears in the second one — substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators"⁸. A withdrawn nomination is not a safety clearance; it means whoever nominated the substance pulled the paperwork. FDA's stated concern on that page remains immunogenicity risk for certain routes, peptide-related impurities, characterization difficulty, and limited safety information⁸.

The bottom line

An advisory committee narrowly recommended BPC-157 for a compounding list, for ulcerative colitis, against the advice of FDA's own scientists, with the entire favorable margin supplied by members appointed weeks earlier. Nothing is listed, nothing is approved, no rule has been proposed, and no athletic indication was ever on the agenda.

For the full meeting — all seven substances, all seven indications, all the tallies — read what actually happened at the FDA peptide advisory vote. For where BPC-157 sits legally alongside the rest of the category, see are peptides legal?. And for the evidence question, which is the one that should actually drive a decision, start with our BPC-157 evidence review and the best recovery peptides hub.